Compare

Afya/$AFYA

1D1W1MYTD1Y5YMAX

About Afya

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Ticker
$AFYA
Primary listing
NASDAQ
Employees
9,395
Headquarters
Belo Horizonte, Brazil

Afya Metrics

BasicAdvanced
$1.1B
7.37
$1.66
0.38
$0.66
5.37%

What the Analysts think about Afya

Analyst ratings (Buy, Hold, Sell) for Afya stock.
Analyst projections of the future price of Afya stock.

Bulls say / Bears say

Afya’s core medical education engine is still expanding: first-half revenue rose 7%, medical-school revenue rose 6.5%, the medical student base grew 2.7% and net average fees rose 3.9%. Management also reaffirmed its 2026 revenue and adjusted EBITDA guidance. (Nasdaq)
Strong cash generation and a conservative balance sheet give Afya room to invest while returning capital. It returned R$447.9 million to shareholders in the first half of 2026, while Moody’s maintained its AAA.br rating with a stable outlook. (Nasdaq, Business Wire)
The proposed Yduqs combination could give Afya greater scale and cost efficiencies. The companies estimate about R$2 billion of synergies, while Afya shareholders would own roughly 69% of a group with annual revenue of about R$9.4 billion. (Valor International, SEC filing)
Growth is becoming more expensive. First-half adjusted EBITDA rose only 2.8% against 7% revenue growth, with the margin falling 190 basis points as Afya invested in continuing education and medical-practice products; management also said AI tools are pressuring Whitebook’s payer base. (Nasdaq, Exa)
Afya’s medical-seat advantage remains dependent on Brazilian regulation, while court-backed course openings are increasing competitive pressure. Its annual filing warns that changing authorisations, enrolment caps and public funding rules can hurt the business, and recent reporting says mature programmes may face margin pressure as new seats enter the market. (SEC filing, Valor International)
The Yduqs transaction brings execution and trading risks before any synergies are realised. It still needs shareholder and regulatory approvals, may not close until March 2028, and would remove AFYA’s Nasdaq listing in favour of a sole B3 listing, potentially reducing accessibility and liquidity for US investors. (SEC filing, Valor International)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.

Afya Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Afya Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.